The global polycystic ovarian syndrome treatment market size reached US$ 3.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.7 Million by 2028, exhibiting a growth rate (CAGR) of 4.9% during 2023-2028.
Polycystic ovarian syndrome (PCOS) refers to a hormonal disorder that leads to the abnormal and excessive production of male hormones in females. It is characterized by hyperandrogenism, ovulatory dysfunction and the development of polycystic ovaries. The disorder can also cause acne, darkening of the skin, weight gain and missed or irregular menstrual cycles, leading to infertility and development of cysts or small fluid-filled sacs in the ovaries. Some of the commonly used treatment methods for regulating and managing PCOS include oral contraceptives, antiandrogens, insulin-sensitizing agents, antidepressants and anti-obesity medicines, along with various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling.
The increasing prevalence of PCOS across the globe represents one of the key factors driving the growth of the market. Furthermore, rising health consciousness and increasing awareness regarding the available treatment alternatives for PCOS are also driving the market growth. PCOS often leads to hirsutism, obesity, diabetes, infertility and other chronic ailments, which has enhanced the requirement for effective treatment alternatives to manage the disease efficiently. In line with this, widespread adoption of laparoscopic ovarian drilling, which involves the surgical triggering of ovulation in women, as an effective treatment for PCOS, is also contributing to the market growth. Additionally, various technological advancements, such as the development of improved pharmacological agents, including androgen suppressors and peripheral androgen blockers, are also favoring the market growth. Other factors, including rising healthcare expenditure of the individuals, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global polycystic ovarian syndrome treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, surgery type and distribution channel.
Breakup by Drug Class:
- Oral Contraceptives
- Insulin-sensitizing Agent
Breakup by Surgery Type:
- Ovarian Wedge Resection
- Laparoscopic Ovarian Drilling
Breakup by Distribution Channel:
- Hospitals and Clinics
- Retail Pharmacies
- Online Stores
Breakup by Region:
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Company, Ferring B.V., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis
||Drug Class, Surgery Type, Distribution Channel, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Abbott Laboratories, AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Company, Ferring B.V., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global polycystic ovarian syndrome treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global polycystic ovarian syndrome treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the surgery type?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global polycystic ovarian syndrome treatment market and who are the key players?
- What is the degree of competition in the industry?